Marketdash
Back to News

Medtronic's Cardiovascular and Diabetes Devices Are Flying Off the Shelves

MarketDash Editorial Team
20 days ago
Medtronic crushed its second-quarter expectations with nearly $9 billion in sales and 5.5% organic growth, driven by surging demand in its cardiovascular and diabetes divisions. The medical device giant is now raising its full-year guidance.

Medtronic Plc (MDT) is having a moment. The medical device maker reported second-quarter 2026 results on Tuesday that beat expectations handily, with sales reaching $8.96 billion against analyst estimates of $8.87 billion. That's a 6.6% jump year-over-year, with organic growth clocking in at a solid 5.5%.

Adjusted earnings of $1.36 per share also sailed past expectations of $1.31, suggesting the company is finding ways to convert revenue growth into bottom-line results.

Where the Growth Is Coming From

The real story here is in the details. Medtronic's Cardiovascular Portfolio is absolutely crushing it, with revenue hitting $3.436 billion, up 10.8% overall and 9.3% on an organic basis. The Cardiac Rhythm & Heart Failure segment saw mid-teens growth, Structural Heart & Aortic climbed in the high-single digits, and even the Coronary & Peripheral Vascular business managed low-single digit gains.

The diabetes business also turned in an impressive performance, with revenue of $757 million representing a 10.3% increase overall and 7.1% organic growth. That's meaningful momentum in a competitive market.

Meanwhile, the Neuroscience division increased 4.5% to $2.562 billion, driven by high-single digit growth in Neuromodulation and mid-single digit gains in Cranial & Spinal Technologies. Specialty Therapies stayed flat. The Medical Surgical segment grew 2.1% to $2.171 billion, with low-single digit organic increases in both Surgical & Endoscopy and Acute Care & Monitoring.

What Management Is Saying

"...Overall, procedure volumes and our end markets are robust, and we're executing well across the business," said Geoff Martha, Medtronic's chairman and CEO. That's executive-speak for "things are going really well right now."

CFO Thierry Piéton added some color on how the company is managing its finances: "In the second quarter, we drove underlying efficiency gains in our gross margin, significantly increased R&D to fuel our future growth, as well as strategically increased investment in sales and marketing for our growth programs in light of the outsized demand and building momentum for key programs." Translation: They're seeing strong demand and are willing to invest more in sales and R&D to capitalize on it.

"Given our outperformance in the first half of the year and confidence we have in our revenue growth acceleration, we are raising today our full-year revenue and EPS guidance," Piéton continued.

Raising the Bar

Speaking of guidance, Medtronic bumped up its fiscal year 2026 organic revenue growth forecast to 5.5% from 5%. The company also raised its adjusted earnings outlook to $5.62-$5.66 per share, up from the prior range of $5.60-$5.66, and slightly above the analyst consensus of $5.63.

There's a small cloud on the horizon: the guidance includes a potential tariff impact of approximately $185 million, unchanged from previous estimates. Strip out that tariff headwind, and the guidance represents fiscal 2026 adjusted earnings per share growth of approximately 4.5%.

Price Action: MDT stock was trading higher by 4.28% to $100.40 in premarket trading Tuesday.

Back to News

Medtronic's Cardiovascular and Diabetes Devices Are Flying Off the Shelves

MarketDash Editorial Team
20 days ago
Medtronic crushed its second-quarter expectations with nearly $9 billion in sales and 5.5% organic growth, driven by surging demand in its cardiovascular and diabetes divisions. The medical device giant is now raising its full-year guidance.

Medtronic Plc (MDT) is having a moment. The medical device maker reported second-quarter 2026 results on Tuesday that beat expectations handily, with sales reaching $8.96 billion against analyst estimates of $8.87 billion. That's a 6.6% jump year-over-year, with organic growth clocking in at a solid 5.5%.

Adjusted earnings of $1.36 per share also sailed past expectations of $1.31, suggesting the company is finding ways to convert revenue growth into bottom-line results.

Where the Growth Is Coming From

The real story here is in the details. Medtronic's Cardiovascular Portfolio is absolutely crushing it, with revenue hitting $3.436 billion, up 10.8% overall and 9.3% on an organic basis. The Cardiac Rhythm & Heart Failure segment saw mid-teens growth, Structural Heart & Aortic climbed in the high-single digits, and even the Coronary & Peripheral Vascular business managed low-single digit gains.

The diabetes business also turned in an impressive performance, with revenue of $757 million representing a 10.3% increase overall and 7.1% organic growth. That's meaningful momentum in a competitive market.

Meanwhile, the Neuroscience division increased 4.5% to $2.562 billion, driven by high-single digit growth in Neuromodulation and mid-single digit gains in Cranial & Spinal Technologies. Specialty Therapies stayed flat. The Medical Surgical segment grew 2.1% to $2.171 billion, with low-single digit organic increases in both Surgical & Endoscopy and Acute Care & Monitoring.

What Management Is Saying

"...Overall, procedure volumes and our end markets are robust, and we're executing well across the business," said Geoff Martha, Medtronic's chairman and CEO. That's executive-speak for "things are going really well right now."

CFO Thierry Piéton added some color on how the company is managing its finances: "In the second quarter, we drove underlying efficiency gains in our gross margin, significantly increased R&D to fuel our future growth, as well as strategically increased investment in sales and marketing for our growth programs in light of the outsized demand and building momentum for key programs." Translation: They're seeing strong demand and are willing to invest more in sales and R&D to capitalize on it.

"Given our outperformance in the first half of the year and confidence we have in our revenue growth acceleration, we are raising today our full-year revenue and EPS guidance," Piéton continued.

Raising the Bar

Speaking of guidance, Medtronic bumped up its fiscal year 2026 organic revenue growth forecast to 5.5% from 5%. The company also raised its adjusted earnings outlook to $5.62-$5.66 per share, up from the prior range of $5.60-$5.66, and slightly above the analyst consensus of $5.63.

There's a small cloud on the horizon: the guidance includes a potential tariff impact of approximately $185 million, unchanged from previous estimates. Strip out that tariff headwind, and the guidance represents fiscal 2026 adjusted earnings per share growth of approximately 4.5%.

Price Action: MDT stock was trading higher by 4.28% to $100.40 in premarket trading Tuesday.